PRO131921

DRUG2 trials

Sponsors

Genentech, Inc.

Conditions

Chronic Lymphocytic LeukemiaNon-Hodgkin's Lymphoma

Phase 1

A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

TerminatedNCT00452127

Genentech, Inc.Non-Hodgkin's Lymphoma

Start: 2007-05-31Updated: 2013-01-28

A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

TerminatedNCT00496132

Genentech, Inc.Chronic Lymphocytic Leukemia

Start: 2007-08-27End: 2009-06-17Updated: 2017-07-02